IMFINZI®, IMJUDO®, Lenvatinib, and TACE Combination Reduces Disease Progression or Death Risk by 30% in Liver Cancer Patients

A recent Phase III trial, EMERALD-3, revealed that the combination of IMFINZI® (durvalumab) and IMJUDO® (tremelimumab-actl) alongside lenvatinib and transarterial chemoembolization (TACE) significantly improved outcomes for patients with embolization-eligible unresectable hepatocellular carcinoma (HCC). The study demonstrated that this combined therapeutic approach reduced the risk of disease progression or death by 30% compared to TACE alone.

Specifically, the EMERALD-3 trial focused on patients with liver cancer who were eligible for embolization but could not undergo surgery. Researchers found that adding IMFINZI®, IMJUDO®, and lenvatinib to the standard TACE treatment resulted in a notable decrease in the likelihood of disease worsening or death. This finding suggests a potential new treatment option for individuals facing this challenging form of liver cancer.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 1, 2026

Author

GOAI